Biomea Fusion develops oral drug candidates to treat diabetes and obesity. It last closed at $0.57 on Nov 20, down 2.38% on the day. The next earnings report for BMEA is expected around Tue, Feb 2, 2027, after the close. For the quarter ended Sep 2026, BMEA reported EPS of -$0.09. Over its last 8 reports the stock moved an average of 7.0% the session after earnings. Over the last 12 months BMEA insiders bought $196K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is BMEA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BMEA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BMEAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BMEA · as of the Nov 20 close · updated each morning
Downtrend
The stock is 3% below its 20 day and 75% below its 50 day average. It is 130% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot at $0.57, and the nearest resistance the 20 day average at $0.59.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 14.2%/day
Key levels
$2.2452 week high+293.0%
$1.32200 day average+131.6%
$1.22100 day average+114.0%
$1.0050 day average+75.4%
$0.63Swing high (Nov 12)+10.5%
$0.60Pivot R1+5.3%
$0.5920 day average+3.5%
$0.57Pivot+0.0%
$0.57Last close
$0.55Pivot S1−3.5%
$0.55Swing low (Oct 26)−3.5%
$0.4552 week low−21.1%
Indicators
RSI (14)
38.64
Weak, oversold below 30
Neutral
MACD
-0.12
Above its signal line
Bullish
Stochastic
47.2
Middle of its range
Neutral
ADX (14)
44.7
Strong downtrend
Williams %R
-48.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-34.9
Oversold below −100, overbought above 100
Neutral
Rate of change
+1.3%
Change over 10 sessions
Bullish
ATR (14)
$0.08
Typical daily range, 14.2% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 44.4%/day
Key levels
$2.2452 week high+293.0%
$1.32200 day average+131.6%
$1.22100 day average+114.0%
$1.0050 day average+75.4%
$0.63Swing high (Nov 12)+10.5%
$0.60Pivot R1+5.3%
$0.5920 day average+3.5%
$0.57Pivot+0.0%
$0.57Last close
$0.55Pivot S1−3.5%
$0.55Swing low (Oct 26)−3.5%
$0.4552 week low−21.1%
Indicators
RSI (14)
35.33
Weak, oversold below 30
Neutral
MACD
-0.22
Below its signal line
Bearish
Stochastic
4.1
Near the bottom of its range
Oversold
ADX (14)
16.6
No clear trend
Williams %R
-92.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-139.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−67.0%
Change over 10 sessions
Bearish
ATR (14)
$0.26
Typical daily range, 44.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BMEA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BMEA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow BMEA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BMEAHow many large options trades hit BMEA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BMEA in the last 90 days.
From SEC Form 4 filings by BMEA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMEA is in one of them and how their past BMEA trades turned out.
Biomea Fusion is a drug developer focused on treatments for diabetes, obesity, and related metabolic diseases. Its work centers on two experimental medicines taken by mouth: icovamenib, which is being studied in type 1 and type 2 diabetes, and BMF-650, a next generation GLP-1 receptor agonist being developed for obesity. The company is based in San Carlos, California, and its target customers are patients with these conditions and the doctors who treat them. Both medicines are still in clinical development.